Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10211926 | Clinical Lymphoma Myeloma and Leukemia | 2018 | 22 Pages |
Abstract
Retrospective analysis revealed that BCL-2+ and BCL-2+/MYC+ were prognostic factors indicative of poor outcomes. Patients with BCL-2+ and/or MYC+ expression had a poorer prognosis than that of patients with BCL-2â and/or MYCâ expression. Patients with BCL-2+/MYCâ expression showed a trend toward poorer survival than those with BCL-2â/MYC+ expression, suggesting that BCL-2 plays a more important role than MYC. Also, patients with BCL-6â/MYC+ expression had poorer progression-free survival than those with BCL-6+/MYC+ expression. In addition, patients with BCL-2+/MYC+/BCL-6â expression had the worst prognosis, suggesting that BCL-6â is a prognostic factor for poor outcomes for MYC+ DLBCL patients. Altogether, our findings have shown that BCL-2 is an independent prognostic factor and possibly plays a more important role than MYC in MYC+ DLBCL patients. Furthermore, we found that BCL-6â expression could also be a prognostic factor portending poor outcomes for MYC+ DLBCL patients.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Linyu Li, Xuhan Zhang, Tingting Zhang, Zheng Song, Ge Hu, Wei Li, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Xianming Liu, Lixia Feng, Yi Pan, Qiongli Zhai, Bin Meng, Xiubao Ren, Kai Fu, Ping Wang, Huilai Zhang,